People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...
The conference also served to educate the attendees about UAMS' Odyssey Clinic. Dr. Craig Jones, the clinic's program manager, said it opened July 1 and works with schizophrenia patients 16 years or ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
CNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy ...
Bristol Myers Squibb has received U.S. FDA approval for a new schizophrenia drug, marking the first new antipsychotic medication in decades. The drug, Cobenfy, lacks warnings about increased mortality ...
The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback